TATIANA ZAMBRANO FILOMENSKY
Índice h a partir de 2011
5
Projetos de Pesquisa
Unidades Organizacionais
Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
- The need to consume: Hoarding as a shared psychological feature of compulsive buying and binge eating(2018) MATTOS, Cristiana Nicoli de; KIM, Hyoun S.; LACROIX, Emilie; REQUIAO, Marinalva; FILOMENSKY, Tatiana Zambrano; HODGINS, David C.; TAVARES, HermanoIntroduction: Compulsive buying and binge eating are two frequently co-occurring psychiatric conditions. Hoarding, which is the psychological need to excessively gather and store items, is frequently associated with both compulsive buying severity and binge eating severity. In the present study, we explored whether different dimensions of hoarding are a shared feature of compulsive buying and binge eating. Method: Participants consisted of 434 people seeking treatment for compulsive buying disorder. Registered psychiatrists confirmed the diagnosis of compulsive buying through semi-structured clinical interviews. Participants also completed measures to assess compulsive buying severity, binge eating severity, and dimensions of hoarding (acquisition, difficulty discarding, and clutter). Two-hundred and seven participants completed all three measures. Results: Significant correlations were found between compulsive buying severity and the acquisition dimension of hoarding. Binge eating severity was significantly correlated with all three dimensions of hoarding. Hierarchical regression analysis found that compulsive buying severity was a significant predictor of binge eating severity. However, compulsive buying severity no longer predicted binge eating severity when the dimensions of hoarding were included simultaneously in the model. Clutter was the only subscale of hoarding to predict binge eating severity in step two of the regression analysis. Conclusion: Our results suggest that the psychological need to excessively gather and store items may constitute a shared process that is important in understanding behaviors characterized by excessive consumption such as compulsive buying and binge eating.
bookPart Compras compulsivas(2015) FILOMENSKY, Tatiana Zambrano; VASCONCELOS, Ana Maria Carlstron; GUIMARãES, Cleide Maria Bartholi; REQUIãO, Marinalva Gonçalves; MARANSALDI, Renata Fernandes; FERREIRA, Sônia Maria Estácio- Gender Differences in Compulsive Buying Disorder: Assessment of Demographic and Psychiatric Co-Morbidities(2016) MATTOS, Cristiana Nicoli de; KIM, Hyoun S.; REQUIAO, Marinalva G.; MARASALDI, Renata F.; FILOMENSKY, Tatiana Z.; HODGINS, David C.; TAVARES, HermanoCompulsive buying is a common disorder found worldwide. Although recent research has shed light into the prevalence, etiology and clinical correlates of compulsive buying disorder, less is known about gender differences. To address this empirical gap, we assessed potential gender differences in demographic and psychiatric co-morbidities in a sample of 171 compulsive buyers (20 men and 151 women) voluntarily seeking treatment in Sao Paulo, Brazil. A structured clinical interview confirmed the diagnosis of compulsive buying. Of the 171 participants, 95.9% (n = 164) met criteria for at least one co-morbid psychiatric disorder. The results found that male and female compulsive buyers did not differ in problem severity as assessed by the Compulsive Buying Scale. However, several significant demographic and psychiatric differences were found in a multivariate binary logistic regression. Specifically, male compulsive buyers were more likely to report being non-heterosexual, and reported fewer years of formal education. In regards to psychiatric co-morbidities, male compulsive buyers were more likely to be diagnosed with sexual addiction, and intermittent explosive disorder. Conversely, men had lower scores on the shopping subscale of the Shorter PROMIS Questionnaire. The results suggest that male compulsive buyers are more likely to present with co-morbid psychiatric disorders. Treatment planning for compulsive buying disorder would do well to take gender into account to address for potential psychiatric co-morbidities.
bookPart Escalas de outros comportamentos impulsivos(2016) ABREU, Cristiano Nabuco; TOLEDO, Edson Luiz; TAVARES, Hermano; LEITE, Priscila Lourenço; FILOMENSKY, Tatiana ZambranobookPart Compras compulsivas(2022) FILOMENSKY, Tatiana Zambrano; VASCONCELOS, Ana Maria Carlstron; CASTRO, Andreia Fernanda da Silva; GUIMARãES, Cleide Maria Bartholi; MATTOS, Cristiana Nicoli de; GONçALVES, Marcelo Peixoto; REQUIãO, Marinalva Gonçalves; MARANSALDI, Renata Fernandes; FERREIRA, Sonia Maria Estácio; COUTO, Tânia Mara MarianoconferenceObject Impulse control disorder and addictive behaviors in compulsive buying disorder patients within and without the bipolar spectrum(2023) MARANSALDI, Renata Fernandes; FILOMENSKY, Tatiana Zambrano; TAVARES, Hermano- A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topiramate for the Treatment of Compulsive Buying Disorder(2020) MATTOS, Cristiana de; KIM, Hyoun S.; MARASALDI, Renata F.; REQUIAO, Marinalva G.; OLIVEIRA, Elen Cristina de; FILOMENSKY, Tatiana; TAVARES, HermanoBackground Topiramate is an anticonvulsant that has shown promise as a pharmacological agent for the treatment of addictive disorders, including compulsive buying disorder (CBD). The aim of the present study was to examine the efficacy of topiramate in the treatment of CBD and its associated characteristics using a 12-week randomized, double-blind, placebo-controlled design. Methods Fifty patients seeking treatment of CBD who met the inclusion criteria were randomly assigned to either the experimental group (n = 25) or the control group (n = 25). Both groups received 4 sessions of psychoeducation. Results Forty-four participants completed the follow-up with no differences in the rate of dropout between groups. There were no differences between participants who received topiramate or placebo in reducing CBD symptoms assessed by the primary outcome scale (Yale-Brown Obsessive-Compulsive Scale - Shopping Version). However, participants who received topiramate were significantly more likely to show clinical improvement when assessed by a secondary outcome measure, the Compulsive Buying Follow-Up Scale. In addition, there was a trend among participants who received topiramate to report improvements in aspects of hoarding and impulsivity compared with the control group. There were significant improvements in comorbid depression and social adjustments over time, but no group x time interaction was found. Conclusions The results do not provide support for the use of topiramate in the treatment of CBD. Future investigation with larger and representative samples and longer follow-up period are needed.
- Neither bipolar nor obsessive-compulsive disorder: compulsive buyers are impulsive acquirers(2012) FILOMENSKY, Tatiana Zambrano; ALMEIDA, Karla Mathias; NOGUEIRA, Marcelo Campos Castro; DINIZ, Juliana Belo; LAFER, Beny; BORCATO, Sonia; TAVARES, HermanIntroduction: Compulsive buying (CB) is currently classified as an impulse control disorder (ICD) not otherwise classified. Compulsive buying prevalence is estimated at around 5% of the general population. There is controversy about whether CB should be classified as an ICD, a subsyndromal bipolar disorder (BD), or an obsessive-compulsive disorder (OCD) akin to a hoarding syndrome. To further investigate the appropriate classification of CB, we compared patients with CB, BD, and OCD for impulsivity, affective instability, hoarding, and other OCD symptoms. Method: Eighty outpatients (24 CB, 21 BD, and 35 OCD) who were neither manic nor hypomanic were asked to fill out self-report questionnaires. Results: Compulsive buying patients scored significantly higher on all impulsivity measures and on acquisition but not on the hoarding subdimensions of clutter and ""difficulty discarding."" Patients with BD scored higher on the mania dimension from the Structured Clinical Interview for Mood Spectrum scale. Patients with OCD scored higher on obsessive-compulsive symptoms and, particularly, higher on the contamination/washing and checking dimensions from the Padua Inventory; however, they did not score higher on any hoarding dimension. A discriminant model built with these variables correctly classified patients with CB (79%), BD (71%), and OCD (77%). Conclusion: Patients with CB came out as impulsive acquirers, resembling ICD- rather than BD- or OCD-related disorders. Manic symptoms were distinctive of patients with BD. Hoarding symptoms other than acquisition were not particularly associated with any diagnostic group.
- Development and validation of the compulsive-buying follow-up scale: A measure to assess treatment improvements in compulsive buying disorder(2019) MATTOS, Cristiana Nicoli de; KIM, Hyoun S.; FILOMENSKY, Tatiana Zambrano; TAVARES, HermanoThe aim of the present research was to develop a scale to assess treatment improvements for compulsive buying disorder (CBD), adapted from the Gambling Follow-up Scale Self-Report Version. The Compulsive Buying Follow-up Scale (CBFS) contains six self-report multiple-choice items assessing different aspects of compulsive buying in the past four weeks. Forty-eight treatment-seeking patients with CBD were evaluated, with 39 patients completing the 12-week follow-up. The scale's global alpha was high as well as the item-total correlations per item. The estimations of alpha if-item-deleted were all under the global alpha value, indicating that all items provided relevant contribution within the scale. The CBFS demonstrated significant correlations with previously developed scales of CBD and other measures of psychopathology, with the exception of a non-significant association with the Beck Depression Inventory at pre-treatment. The CBFS correlated significantly with all reference scales at post-treatment. The CBFS also demonstrated strong sensitivity to change and recovery status. The cutoff for the CBFS that provided the greatest sensitivity (0.93) and specificity (0.82) was 22. The results provide support that CBFS is a reliable and valid instrument to measure treatment outcomes over time for CBD.